Literature DB >> 25969500

Postoperative cystoid macular oedema in a patient on fingolimod.

Jennifer Chen-Chia Fan Gaskin1, Michael Coote2.   

Abstract

We describe the first case of fingolimod-associated bilateral cystoid macular oedema (CMO) following uncomplicated cataract surgery. A 57-year-old woman has been on fingolimod for the past 2 years for the treatment of relapsing-remitting multiple sclerosis. She underwent uneventful consecutive cataract surgery 2 weeks apart. Three weeks following the second cataract operation, she reported gradual-onset blurred vision bilaterally. Examination revealed mildly reduced visual acuity and bilateral CMO. Treatment with topical corticosteroids and non-steroidal anti-inflammatory eye drops, as well as cessation of fingolimod in collaboration with the neurologist, resulted in complete resolution of the CMO. Patients on fingolimod are likely to be at increased risk of developing postoperative CMO. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25969500      PMCID: PMC4434361          DOI: 10.1136/bcr-2015-210415

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Detection of cystoid macular edema with three-dimensional optical coherence tomography versus fluorescein angiography.

Authors:  Yanling Ouyang; Pearse A Keane; Srinivas R Sadda; Alexander C Walsh
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-31       Impact factor: 4.799

2.  Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient.

Authors:  Georges Saab; Arghavan Almony; Kevin J Blinder; Rebecca Schuessler; Daniel C Brennan
Journal:  Arch Ophthalmol       Date:  2008-01

3.  Controversies in the management of Irvine-Gass syndrome.

Authors:  Daniel F Kiernan; Seenu M Hariprasad
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2013-11-01       Impact factor: 1.300

4.  4-Aminopyridine: new life for an old drug. Reply.

Authors:  Ron Cohen; Andrew R Blight
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

5.  Cystoid macular edema associated with fingolimod use for multiple sclerosis.

Authors:  Armin R Afshar; Joshua K Fernandes; Ravi D Patel; Susan M Ksiazek; Veeral S Sheth; Anthony T Reder; Seenu M Hariprasad
Journal:  JAMA Ophthalmol       Date:  2013-01       Impact factor: 7.389

Review 6.  Fingolimod-associated macular edema: incidence, detection, and management.

Authors:  Nieraj Jain; M Tariq Bhatti
Journal:  Neurology       Date:  2012-02-28       Impact factor: 9.910

7.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing.

Authors:  K Chiba; Y Yanagawa; Y Masubuchi; H Kataoka; T Kawaguchi; M Ohtsuki; Y Hoshino
Journal:  J Immunol       Date:  1998-05-15       Impact factor: 5.422

8.  FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia.

Authors:  M Salvadori; K Budde; B Charpentier; J Klempnauer; B Nashan; L M Pallardo; J Eris; F P Schena; U Eisenberger; L Rostaing; A Hmissi; S Aradhye
Journal:  Am J Transplant       Date:  2006-12       Impact factor: 8.086

9.  Does fingolimod in multiple sclerosis patients cause macular edema?

Authors:  Kiran Turaka; Joseph Shepard Bryan
Journal:  J Neurol       Date:  2012-01-10       Impact factor: 4.849

10.  Postsurgical inflammation after phacoemulsification and extracapsular extraction with soft or conventional intraocular lens implantation.

Authors:  T Oshika; K Yoshimura; N Miyata
Journal:  J Cataract Refract Surg       Date:  1992-07       Impact factor: 3.351

  10 in total
  4 in total

1.  Fingolimod-associated severe bilateral cystoid macular edema.

Authors:  Hideki Fukuoka; Kentaro Kojima; Ayako Iwama; Takahiro Okumura; Chie Sotozono
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-22

Review 2.  Fingolimod: therapeutic mechanisms and ocular adverse effects.

Authors:  P Mandal; A Gupta; W Fusi-Rubiano; P A Keane; Y Yang
Journal:  Eye (Lond)       Date:  2016-11-25       Impact factor: 3.775

Review 3.  Ocular adverse events from pharmacological treatment in patients with multiple sclerosis-A systematic review of the literature.

Authors:  Juliana Muñoz-Ortiz; Juliana Reyes-Guanes; Estefanía Zapata-Bravo; Laura Mora-Muñoz; Juan Antonio Reyes-Hurtado; Luis Octavio Tierradentro-García; William Rojas-Carabali; Marcela Gómez-Suarez; Alejandra de-la-Torre
Journal:  Syst Rev       Date:  2021-10-28

4.  Diagnosis and Management of Fingolimod-Associated Macular Edema.

Authors:  Chunjiang Wang; Zhenzhen Deng; Liying Song; Wei Sun; Shaoli Zhao
Journal:  Front Neurol       Date:  2022-07-15       Impact factor: 4.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.